"Multiple sclerosis: three trials to watch" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK ...

Knight Therapeutics Inc., (TSX: GUD) ('Knight') a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate, Laboratorio LKM S.A. has obtained the regulatory ...

AI-advanced drug candidate achieves complete metabolic response after two cycles in patient who failed CAR-T and bispecific ...

The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling strong interest in novel mechanisms of action and shifting away from legacy regimens, ...

The stock is trading at $5.69, up 2.92, gaining 105.40% on volume of over 61 Million shares. The stock had a morning high of ...

Brepocitinib’s once-daily oral administration, coupled with its dual mechanism of action, is seen as offering meaningful ... and poor responses to existing regimens including IVIg, rituximab, and ...

Investing.com -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) stock soared 100% in after-hours trading on Thursday after the company announced it received FDA Fast Track Designation for its AlloNK ...

THIS AUTUMN, Paris, France, hosted the 34ᵗʰ annual European Academy of Dermatology and Venereology (EADV) Congress.

DelveInsight’s, “Mantle Cell Lymphoma- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and ...

A research team led by Prof. Ben Ko Chi-bun, Associate Professor of the PolyU Department of Applied Biology and Chemical Technology, has discovered the critical mechanism of action of tetrandrine, a ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...